



CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Beebe Healthcare

May 15, 2019

EDEN PRAIRIE, Minn., May 15, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announces that Sussex County, Delaware-based health system, Beebe Healthcare, has initiated offering ultrafiltration therapy using the company's Aquadex FlexFlow system.

"As heart failure and other conditions that contribute to fluid overload expand worldwide, CHF continues to provide a proven solution for managing this patient population to improve their quality of life and reducing the cost of care," said John Erb, CEO of CHF Solutions. "We are proud to be a part of the Beebe Healthcare system and look forward to partnering with Beebe's clinicians in the care of their fluid overloaded patients."

"This treatment has become a very viable and useful alternative for appropriate heart failure patients, and we are excited to have it available at Beebe Healthcare," said Alberto Rosa, MD, Medical Director of Heart Failure. "The Aquadex FlexFlow system gives us a wonderful option for treating patients and keeping them comfortable when they no longer respond to diuretics."

Lynn Toth, DNP, MSN, RN, NP-C, Cardiovascular Medical Specialist added, "There are many potential uses for aquapheresis as the Beebe program grows, from weekly treatments that allow heart failure patients to manage their fluid build-up, to fluid removal that enables patients to undergo surgery."

Beebe Healthcare serves a rapidly growing community with several campuses located throughout Sussex County, Delaware. The Margaret H. Rollins Lewes Campus, is home to the health system's 210 licensed-bed acute care hospital. In 2019, Beebe opened the Center for Robotic Surgery, which features multiple specialties. Beebe's Rehoboth Health Campus near Rehoboth Beach is home to the Tunnell Cancer Center as well as several outpatient services. In May 2019, Beebe will break ground for a Specialty Surgical Hospital on that campus, which will serve as the regional hub for short-stay elective surgeries. Beebe also operates outpatient locations in Georgetown, Millsboro, Milton, and Millville. In 2020, Beebe will open their South Coastal Health Campus near Millville, which will feature a freestanding emergency room and second comprehensive cancer center. Founded in 1916, Beebe Healthcare is a not-for-profit health system, and many programs and facilities are made possible by the generous support of the community. Specialty services include: cardiac and vascular, general and specialty surgery, oncology, women's health, and orthopedics as well as ancillary and post-acute services. Additionally, through the Beebe Medical Group, Beebe Healthcare operates four walk-in centers and over 20 physician practices representing over 40 specialties.

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow System for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom have received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements relating to potential uses for aquapheresis and the Aquadex FlexFlow System. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-
Bret Shapiro
Managing
Partner CORE
IR

516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
Source: CHF Solutions, Inc.

chf solutions

Source: CHF Solutions, Inc.